Literature DB >> 10852125

Virus and target cell evolution in human immunodeficiency virus type 1 infection.

D E Mosier1.   

Abstract

Human immunodeficiency virus (HIV) infection leads to a prolonged struggle between a rapidly evolving viral population and a potent immune response. In the vast majority of infected individuals, the virus wins this struggle. In my laboratory, we focus on understanding both the viral and immune factors that contribute to this outcome. The results of our studies and those of many others indicate that HIV can escape a potent immune response by a combination of mechanisms including rapid mutation, shedding of decoy antigens, modulation of host major histocompatibility complex, and destruction of cytotoxic T lymphocytes. The target cells for viral infection change as the virus evolves to use different chemokine coreceptors for entry. The initial targets are activated and resting memory T cells that express both CD4 and CCR5, but both naive and memory CD4 T cells are targeted by viruses capable of using CXCR4 for entry, and macrophages become the primary target cells when most CD4 T cells are depleted. Compelling evidence is emerging that the availability of target cells for infection is as limiting for the spread of virus as the immune response.

Entities:  

Mesh:

Year:  2000        PMID: 10852125     DOI: 10.1385/IR:21:2-3:253

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  38 in total

1.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

Review 2.  Dynamics of HIV-1 and CD4+ lymphocytes in vivo.

Authors:  A S Perelson; P Essunger; D D Ho
Journal:  AIDS       Date:  1997       Impact factor: 4.177

3.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

Authors:  D E Mosier; G R Picchio; R J Gulizia; R Sabbe; P Poignard; L Picard; R E Offord; D A Thompson; J Wilken
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes.

Authors:  G R Picchio; R J Gulizia; K Wehrly; B Chesebro; D E Mosier
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors:  K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

Review 7.  HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication.

Authors:  C Jassoy; B D Walker
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Human immunodeficiency virus infection of human-PBL-SCID mice.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson; D H Spector; S A Spector
Journal:  Science       Date:  1991-02-15       Impact factor: 47.728

10.  Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells.

Authors:  X N Xu; G R Screaton; F M Gotch; T Dong; R Tan; N Almond; B Walker; R Stebbings; K Kent; S Nagata; J E Stott; A J McMichael
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

View more
  8 in total

1.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 2.  Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease.

Authors:  Pratip K Chattopadhyay; Mario Roederer
Journal:  Cytometry A       Date:  2010-07       Impact factor: 4.355

Review 3.  Nature, nurture and HIV: The effect of producer cell on viral physiology.

Authors:  Sergey Iordanskiy; Steven Santos; Michael Bukrinsky
Journal:  Virology       Date:  2013-06-05       Impact factor: 3.616

4.  A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.

Authors:  Saki Shimizu; Patrick Hong; Balamurugan Arumugam; Lauren Pokomo; Joshua Boyer; Naoya Koizumi; Panyamol Kittipongdaja; Angela Chen; Greg Bristol; Zoran Galic; Jerome A Zack; Otto Yang; Irvin S Y Chen; Benhur Lee; Dong Sung An
Journal:  Blood       Date:  2009-12-17       Impact factor: 22.113

5.  Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo.

Authors:  Nelson C Di Paolo; Edward A Miao; Yoichiro Iwakura; Kaja Murali-Krishna; Alan Aderem; Richard A Flavell; Thalia Papayannopoulou; Dmitry M Shayakhmetov
Journal:  Immunity       Date:  2009-07-02       Impact factor: 31.745

6.  CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection.

Authors:  Alison Motsinger; David W Haas; Aleksandar K Stanic; Luc Van Kaer; Sebastian Joyce; Derya Unutmaz
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

7.  Trade-offs in antibody repertoires to complex antigens.

Authors:  Lauren M Childs; Edward B Baskerville; Sarah Cobey
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

Review 8.  Progress on RNAi-based molecular medicines.

Authors:  Jing Chen; Jianping Xie
Journal:  Int J Nanomedicine       Date:  2012-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.